Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
暂无分享,去创建一个
M. Lux | M. Beckmann | P. Fasching | T. Fehm | A. Schneeweiss | D. Wallwiener | H. Tesch | V. Müller | W. Janni | N. Nabieva | F. Taran | M. Wallwiener | S. Brucker | A. Hartkopf | A. Wöckel | J. Ettl | P. Hadji | D. Lüftner | F. Schütz | H. Kolberg | F. Overkamp | E. Belleville
[1] M. Lux,et al. Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention , 2018, Geburtshilfe und Frauenheilkunde.
[2] S. Loibl,et al. Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients , 2018 .
[3] P. Fasching,et al. Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69 , 2018 .
[4] R. Gelber,et al. Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials , 2018 .
[5] P. Neven,et al. Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study) , 2018 .
[6] R. Greil,et al. Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial , 2018 .
[7] J. Bergh,et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials , 2018 .
[8] David Evans,et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.
[9] P. Fasching. Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? , 2018, The Lancet. Oncology.
[10] Mike Clarke,et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials , 2018, The Lancet. Oncology.
[11] H. Putter,et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) , 2018, Journal of the National Cancer Institute.
[12] D. Cescon,et al. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.
[13] P. Neven,et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[14] C. Sotiriou,et al. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial , 2017 .
[15] P. Fasching,et al. Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer? , 2017, Geburtshilfe und Frauenheilkunde.
[16] M. Lux,et al. Update Breast Cancer 2017 – Implementation of Novel Therapies , 2017, Geburtshilfe und Frauenheilkunde.
[17] J. Qin,et al. ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy , 2017, OncoTargets and therapy.
[18] P. Fasching,et al. Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2- breast cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] L. Pusztai,et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] P. Fasching,et al. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. , 2017, Breast.
[21] N. Zhang,et al. 151PDEfficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer , 2017 .
[22] T. Fehm,et al. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial , 2017, Clinical Cancer Research.
[23] P. Fasching,et al. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). , 2017, Geburtshilfe und Frauenheilkunde.
[24] M. Rezai,et al. Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity , 2017, Oncotarget.
[25] Maristella,et al. Genomic analyses identify hundreds of variants associated with age at menarche and 1 support a role for puberty timing in cancer risk 2 , 2017 .
[26] David Cameron,et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial , 2017, The Lancet.
[27] M. Rezai,et al. Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study , 2014, Geburtshilfe und Frauenheilkunde.
[28] H. Kolberg. Editorial: Primary Systemic Therapy for Breast Cancer. , 2017, Reviews on recent clinical trials.
[29] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[30] H. Baker. Extending aromatase inhibitor adjuvant therapy to 10 years. , 2016, The Lancet. Oncology.
[31] M. Beckmann,et al. Abstract S2-03: Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis – Results from the adjuvant SUCCESS A trial , 2016 .
[32] Tanja Fehm,et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer , 2016, Clinical Cancer Research.
[33] M. Rezai,et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study , 2015, International journal of cancer.
[34] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[35] Andrew D. Johnson,et al. Nature Genetics Advance Online Publication Large-scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility and Brca1-mediated Dna Repair , 2022 .
[36] N. White,et al. Treatment of Ebola. , 2015, The New England journal of medicine.
[37] Peter Kraft,et al. Identification of Novel Genetic Markers of Breast Cancer Survival , 2015, Journal of the National Cancer Institute.
[38] P. Fasching,et al. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients , 2015, Oncotarget.
[39] C. Geyer,et al. Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer , 2015, Annals of Surgical Oncology.
[40] P. Fasching,et al. Breast Cancer Update 2014 - Focus on the Patient and the Tumour. , 2015, Geburtshilfe und Frauenheilkunde.
[41] A. Giobbie-Hurder,et al. Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.
[42] H Tesch,et al. Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. , 2015, Geburtshilfe und Frauenheilkunde.
[43] Andrew D. Johnson,et al. Parent-of-origin specific allelic associations among 106 genomic loci for age at menarche , 2014, Nature.
[44] J. Griggs,et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Tanja Fehm,et al. Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.
[46] M. Lux,et al. Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients , 2014, BioMed research international.
[47] P. Macaskill,et al. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Therapy: A Meta-Analysis , 2014, Annals of Surgical Oncology.
[48] Andrew D. Johnson,et al. DNA mismatch repair gene MSH6 implicated in determining age at natural menopause , 2013, Human molecular genetics.
[49] M. Lux,et al. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients , 2014, BMC Cancer.
[50] M. Espié,et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[51] S. Cross,et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] P. Fasching,et al. Biomarkers in Breast Cancer - An Update. , 2012, Geburtshilfe und Frauenheilkunde.
[53] Jaana M. Hartikainen,et al. The role of genetic breast cancer susceptibility variants as prognostic factors. , 2012, Human molecular genetics.
[54] P. Fasching,et al. Breast Cancer 2012 - New Aspects. , 2012, Geburtshilfe und Frauenheilkunde.
[55] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] E. Perez,et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Peter A Fasching,et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.
[58] A. Giuliano,et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.
[59] J. Fricker. San Antonio Breast Cancer Symposium. , 2009, The Lancet. Oncology.
[60] T. Whelan,et al. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. , 2008, Clinical breast cancer.
[61] M. Bani,et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients , 2008, Breast Cancer Research and Treatment.
[62] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] M. Dowsett,et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.